CA2577883A1 - Proteine de liaison au tnf de type 1 dans le traitement du psoriasis - Google Patents
Proteine de liaison au tnf de type 1 dans le traitement du psoriasis Download PDFInfo
- Publication number
- CA2577883A1 CA2577883A1 CA002577883A CA2577883A CA2577883A1 CA 2577883 A1 CA2577883 A1 CA 2577883A1 CA 002577883 A CA002577883 A CA 002577883A CA 2577883 A CA2577883 A CA 2577883A CA 2577883 A1 CA2577883 A1 CA 2577883A1
- Authority
- CA
- Canada
- Prior art keywords
- treatment
- onercept
- patients
- psoriasis
- pasi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04103954.6 | 2004-08-18 | ||
| EP04103954 | 2004-08-18 | ||
| US60324104P | 2004-08-20 | 2004-08-20 | |
| US60/603,241 | 2004-08-20 | ||
| PCT/IL2005/000841 WO2006018832A1 (fr) | 2004-08-18 | 2005-08-04 | Protéine de liaison au tnf de type 1 dans le traitement du psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2577883A1 true CA2577883A1 (fr) | 2006-02-23 |
Family
ID=34929455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002577883A Abandoned CA2577883A1 (fr) | 2004-08-18 | 2005-08-04 | Proteine de liaison au tnf de type 1 dans le traitement du psoriasis |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1778276A1 (fr) |
| JP (1) | JP2008509989A (fr) |
| AU (1) | AU2005273538A1 (fr) |
| CA (1) | CA2577883A1 (fr) |
| WO (1) | WO2006018832A1 (fr) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU642938B2 (en) * | 1989-12-13 | 1993-11-04 | Yeda Research And Development Co. Ltd. | Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1) |
| WO2005023193A2 (fr) * | 2003-09-04 | 2005-03-17 | Interleukin Genetics, Inc. | Methodes permettant de traiter l'endometriose |
-
2005
- 2005-08-04 CA CA002577883A patent/CA2577883A1/fr not_active Abandoned
- 2005-08-04 AU AU2005273538A patent/AU2005273538A1/en not_active Abandoned
- 2005-08-04 JP JP2007526696A patent/JP2008509989A/ja active Pending
- 2005-08-04 WO PCT/IL2005/000841 patent/WO2006018832A1/fr active Application Filing
- 2005-08-04 EP EP05764287A patent/EP1778276A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1778276A1 (fr) | 2007-05-02 |
| JP2008509989A (ja) | 2008-04-03 |
| AU2005273538A1 (en) | 2006-02-23 |
| WO2006018832A1 (fr) | 2006-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Den Broeder et al. | A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. | |
| Giampietro et al. | Anakinra in Adult‐Onset Still's Disease: Long‐Term Treatment in Patients Resistant to Conventional Therapy | |
| EP3237447B1 (fr) | Anticorps anti-csf1r pour le traitement d'une svnp | |
| Nakashima et al. | Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate | |
| CN111867579B (zh) | Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法 | |
| CN104519900A (zh) | 用于治疗糖尿病的ctla4融合蛋白 | |
| JP2013100313A (ja) | Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法 | |
| CN104507490A (zh) | 用于治疗糖尿病的模式的组合 | |
| Felten et al. | New biologics and targeted therapies in systemic lupus: from new molecular targets to new indications. A systematic review | |
| KR20240055038A (ko) | 다발성 경화증 치료를 위한 lou064 | |
| AU2008324800B2 (en) | Methods of treating scleroderma | |
| JP2023040241A (ja) | ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置 | |
| Oliver et al. | Rheumatoid arthritis/treatment and assesment | |
| CN109475549B (zh) | 药物组合物及其治疗自身免疫疾病的用途 | |
| TWI737000B (zh) | 用於治療化膿性汗腺炎之泛-ｅｌｒ＋ｃｘｃ趨化介素抗體 | |
| EP3864053B1 (fr) | Commutateur d'ofatumumab | |
| CA2577883A1 (fr) | Proteine de liaison au tnf de type 1 dans le traitement du psoriasis | |
| US20030096317A1 (en) | Diagnosis and therapy of antibody-mediated inflammatory auto-immune disorders | |
| US20210277105A1 (en) | Treating ulcerative colitis with brazikumab | |
| Godic | New approaches to psoriasis treatment. A review | |
| KR20220012918A (ko) | 항-cd40 항체의 안전한 투여를 제공하는 방법 | |
| JP2020535140A (ja) | インターロイキン−１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療 | |
| Takeuchi et al. | Possibility of inducing anterior chamber-associated immune deviation by TGF-β2 treatment of monocytes isolated from Behcet's patients | |
| CN113453759A (zh) | 治疗巨细胞动脉炎 | |
| AU2019276779A1 (en) | Treatment of skin diseases or disorders by delivery of anti-osmrbeta antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |